Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UT-15C add-on to oral monotherapy for pulmonary arterial hypertension
NL-OMON44878Phase 3Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Orenitram + background oral monotherapy with Placebo + background oral monotherapy (2 arms). Primary endpoint: Time to first adjudicated clinical worsening event. Started Feb 2014; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON44878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44878.